BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35665592)

  • 1. Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis.
    Li Y; Song Z; Han Q; Zhao H; Pan Z; Lei Z; Zhang J
    Mol Oncol; 2022 Aug; 16(15):2861-2880. PubMed ID: 35665592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway.
    Shang R; Wang M; Dai B; Du J; Wang J; Liu Z; Qu S; Yang X; Liu J; Xia C; Wang L; Wang D; Li Y
    Mol Oncol; 2020 Jun; 14(6):1381-1396. PubMed ID: 32174012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking CD47 promotes antitumour immunity through CD103
    Wang S; Wu Q; Chen T; Su R; Pan C; Qian J; Huang H; Yin S; Xie H; Zhou L; Zheng S
    J Hepatol; 2022 Aug; 77(2):467-478. PubMed ID: 35367532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment.
    Sasaki T; Shigeta K; Kitahara S; Suzuki Y; Matsui S; Seishima R; Okabayashi K; Duda DG; Kitagawa Y
    Anticancer Res; 2022 Nov; 42(11):5205-5215. PubMed ID: 36288859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An "eat me" combinatory nano-formulation for systemic immunotherapy of solid tumors.
    Abdel-Bar HM; Walters AA; Lim Y; Rouatbi N; Qin Y; Gheidari F; Han S; Osman R; Wang JT; Al-Jamal KT
    Theranostics; 2021; 11(18):8738-8754. PubMed ID: 34522209
    [No Abstract]   [Full Text] [Related]  

  • 6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy.
    Zhu H; Shan Y; Ge K; Lu J; Kong W; Jia C
    Cell Oncol (Dordr); 2020 Dec; 43(6):1203-1214. PubMed ID: 32797385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8
    Cai N; Cheng K; Ma Y; Liu S; Tao R; Li Y; Li D; Guo B; Jia W; Liang H; Zhao J; Xia L; Ding ZY; Chen J; Zhang W
    Gut; 2024 May; 73(6):985-999. PubMed ID: 38123979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of phospholipase D1 induces immunogenic cell death and potentiates cancer immunotherapy in colorectal cancer.
    Hwang WC; Song D; Lee H; Oh C; Lim SH; Bae HJ; Kim ND; Han G; Min DS
    Exp Mol Med; 2022 Sep; 54(9):1563-1576. PubMed ID: 36131027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle-Mediated CD47-SIRPα Blockade and Calreticulin Exposure for Improved Cancer Chemo-Immunotherapy.
    Luo JQ; Liu R; Chen FM; Zhang JY; Zheng SJ; Shao D; Du JZ
    ACS Nano; 2023 May; 17(10):8966-8979. PubMed ID: 37133900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promotion of epithelial-mesenchymal transformation by hepatocellular carcinoma-educated macrophages through Wnt2b/β-catenin/c-Myc signaling and reprogramming glycolysis.
    Jiang Y; Han Q; Zhao H; Zhang J
    J Exp Clin Cancer Res; 2021 Jan; 40(1):13. PubMed ID: 33407720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of protein disulfide‑isomerase A3 expression inhibits cell proliferation and induces apoptosis through STAT3 signaling in hepatocellular carcinoma.
    Kondo R; Ishino K; Wada R; Takata H; Peng WX; Kudo M; Kure S; Kaneya Y; Taniai N; Yoshida H; Naito Z
    Int J Oncol; 2019 Apr; 54(4):1409-1421. PubMed ID: 30720090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1.
    Zhang H; Tan YP; Zhao L; Wang L; Fu NJ; Zheng SP; Shen XF
    Cell Death Dis; 2020 Jan; 11(1):63. PubMed ID: 31980595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
    Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
    Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
    Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
    J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant expression of p-STAT3 in peripheral blood CD4+ and CD8+ T cells related to hepatocellular carcinoma development.
    Wang X; Xin W; Zhang H; Zhang F; Gao M; Yuan L; Xu X; Hu X; Zhao M
    Mol Med Rep; 2014 Nov; 10(5):2649-56. PubMed ID: 25175640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8
    Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
    J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.